Dr Felip speaks with ecancer at ESMO 2018 in Munich about research reported at the conference on early lung cancers.

She highlights research from Dr Wu Zhong about erlotinib for EGFRm NSCLC and a combination trial of anti-PD1 and anti-CTLA4 nivolumab and ipilimumab as showing promise.

The use of atezolizumab in 2nd line therapy, presented by Dr Jean-Louis Pujol, was ultimately ineffective, and Dr Felip highlights oerall survival data from the PACIFIC trial as the most significant to clinicians daily practice.

свернуть